This webpage provides drug risk information which has come under review by the PMDA and MHLW. Information provided here is as follows:
Posted Date | Nonproprietary Name | Risk Information of Ongoing Evaluation | Related Information | Investigation Results |
---|---|---|---|---|
October 27, 2023 | Risankizumab (genetical recombination) Ustekinumab (genetical recombination) Guselkumab (genetical recombination) |
Decreased neutrophil count | − | Investigation Appendix: Evaluation of the risk of decreased neutrophil count in patients with antipsoriatics using MID-NET |
December 26, 2013 | Recombinant absorbed bivalent human papillomavirus-like particle vaccine Recombinant adsorbed quadrivalent human papillomavirus virus-like particle vaccine |
Symptoms related to pain | − | Summary of the Report on the Surveillance Results of HPV Vaccines |
Posted Date | Nonproprietary Name | Risk Information of Ongoing Evaluation | Related Information | Investigation Results |
---|---|---|---|---|
November 30, 2011 | Bevacizumab (genetical recombination) | Japan's view on Avastin (bevacizumab) for breast cancer indication | Press Announcement from the FDA Review report of AVASTIN 100mg/4mL Intravenous Infusion and AVASTIN 400mg/16mL Intravenous Infusion on July 14, 2011 (Japanese text only) |
− |